Table 1 Baseline characteristics of patients in Changzhou cohort
Characteristics | Before PSM | p value | After PSM | p value | ||
|---|---|---|---|---|---|---|
HCC group (n = 157) | Control group (n = 734) | HCC group (n = 154) | Control group (n = 154) | |||
Age, \({\overline{\text{x}}}\) ± SD, (year) | 59.66 ± 10.71 | 54.23 ± 13.66 |  < 0.001 | 59.33 ± 10.55 | 58.74 ± 12.35 | 0.652 |
Gender, male, (n, %) | 131 (83.4) | 459 (62.5) |  < 0.001 | 128 (83.1) | 131 (85.1) | 0.755 |
Surveillance time, (day) | 119.56 ± 162.93 | 131.44 ± 230.57 | 0.540 | 121.40 ± 163.97 | 123.54 ± 232.79 | 0.926 |
HBsAg, positive, (n, %) | 126(80.8) | 367 (50) |  < 0.001 | 127 (82.5) | 80 (51.9) |  < 0.001 |
HBeAg, positive, (n, %) | 7(4.5) | 131 (17.9) |  < 0.001 | 7 (4.5) | 30 (19.5) |  < 0.001 |
Liver function | ||||||
ALT, U/L | 31.4 (20.65, 51) | 84 (29, 284) | 0.000 | 31.25 (20.65, 51) | 57.9 (26, 246) | 0.000 |
AST, U/L | 36 (22.5, 61.5) | 63 (31, 168) | 0.000 | 35.5 (22, 61.5) | 54 (29, 149) |  < 0.001 |
Albumin, g/L | 40.6 (35.8, 44) | 39.25 (34.2, 43.3) | 0.024 | 40.8 (35.85, 44) | 38.8 (34.2, 42.4) | 0.008 |
ALP, U/L | 110 (81, 154.5) | 109 (82, 153) | 0.857 | 108.5 (80.5, 153.5) | 113 (82, 152) | 0.764 |
GGT, U/L | 66 (33.6, 156.7) | 99.9 (45.4, 207) |  < 0.001 | 65.35 (32, 154.85) | 115 (46.5, 206) |  < 0.001 |
Total protein, g/L | 68.8 (64.4, 72.55) | 68.6 (63.5, 73.3) | 0.799 | 68.9 (64.65, 72.6) | 68.1 (62.1, 72.8) | 0.311 |
Total bilirubin, umol/L | 17.1 (12.75, 25.5) | 18.95 (13.2, 33.3) | 0.049 | 17.4 (12.85, 25.7) | 18.2 (13.7, 38.2) | 0.092 |
Prothrombin time, s | 13.9 (13.2, 14.7) | 13.9 (12.9, 15.3) | 0.555 | 13.9 (13.2, 14.7) | 13.9 (13.1, 15.5) | 0.897 |
Blood routine | ||||||
WBC, 109/L | 4.94 (3.89, 6.15) | 4.71 (3.71, 6.25) | 0.644 | 4.85 (3.83, 6.14) | 4.87 (3.81, 6.38) | 0.954 |
Platelet, 109/L | 140 (91.5, 195) | 149 (91, 205) | 0.020 | 136.5 (90.5, 191) | 135 (90, 199) | 0.307 |
Neutrophil, 109/L | 3.03 (2.31, 3.93) | 2.7 (1.94, 3.7) | 0.024 | 3.01 (2.30, 3.84) | 2.84 (2.05, 3.84) | 0.367 |
Lymphocyte, 109/L | 1.22 (0.84, 1.70) | 1.4 (1.01, 1.85) | 0.000 | 1.24 (0.84, 1.72) | 1.32 (0.94, 1.77) | 0.055 |
PDW, % | 13.9 (12.5, 15.6) | 14.1 (12.2, 16.7) | 0.161 | 13.9 (12.5, 15.6) | 14.6 (12.3, 17.3) | 0.07 |
MPV, % | 11.4 (10.5, 12) | 11.5 (10.6, 12.4) | 0.114 | 11.45 (10.5, 12) | 11.5 (10.6, 12.5) | 0.035 |
Tumor markers | ||||||
AFP, ng/ml | 21 (3.05, 547.55) | 3.5 (1.9, 12.5) | 0.000 | 20.85 (3.05, 605.75) | 4.3 (2.1, 17.4) | 0.000 |
AFP-L3, % | 10.9 (0.5, 47.3) | 0.5 (0.5, 6.0) | 0.000 | 10.85 (0.5, 45.55) | 0.5 (0.5, 6.8) | 0.000 |
PIVKAII, mAU/ml | 118 (23.5, 3888) | 15 (11, 21) | 0.000 | 125 (23.5, 3888) | 16 (12, 21) | 0.000 |
Tumor AJCC stages* (n, %) | ||||||
Stage I | 77 (49.04) | NA | Â | 75 (48.7) | NA | Â |
Stage II | 31 (19.75) | NA | Â | 30 (19.48) | NA | Â |
Stage III | 27 (17.20) | NA | Â | 27 (17.53) | NA | Â |
Stage IV | 22 (14.01) | NA | Â | 22 (14.29) | NA | Â |